Eagle Pharmaceuticals Inc

NASDAQ:EGRX   3:59:51 PM EDT
54.88
+0.77 (+1.42%)
Products, Strategic Combinations, Regulatory

Eagle Pharmaceuticals Announces Licensing Agreement With Combioxin SA

Published: 08/25/2021 13:38 GMT
Eagle Pharmaceuticals Inc (EGRX) - Eagle Pharmaceuticals Announces Worldwide Licensing Agreement With Combioxin Sa for Phase 2b/3, Novel First-in-class Antitoxin Agent Cal02 in Development for Combination Use With Antibiotics for the Treatment of Severe Pneumonia.
Eagle Pharmaceuticals Inc - Anticipates Ten Years of Regulatory Exclusivity.
Eagle Pharmaceuticals Inc - Eagle Expects to Invest $35 Million to Achieve Interim Results.
Eagle Pharmaceuticals Inc - Interim Results Are Expected in First Half of 2023.
Eagle Pharmaceuticals - Will Be Solely Responsible for Further Clinical Development of Cal02 and Will Make an Upfront Payment.
Eagle Pharmaceuticals Inc - Believes a Cal02 New Drug Application for Treatment of Severe Cabp May Qualify for Priority Review.
Eagle Pharmaceuticals - Plans to Advance Clinical Program and Initiate a Phase 2b/3 Study in First Half of 2022 for Cal02.